Eli Lilly and Company (NYSE:LLY) Stock Falls 2.4% – What’s Next?

Eli Lilly and Company (NYSE:LLY – Get Free Report)’s stock price fell 2.4% during mid-day trading on Wednesday. The stock traded as low as $1,380.00 and last traded at $1,380.9190. 2,575,694 shares were traded during mid-day trading, a decline of 13% from the average daily volume of 2,955,670 shares. The stock had previously closed at $1,415.55.

More Eli Lilly and Company News

Investors following LLY have been watching these news items:

  • Positive Sentiment: ETFs bought about $141.8 million of LLY shares on Nov. 16, indicating substantial fund demand. ETF holdings article
  • Neutral Sentiment: Lilly announced a cancer research and licensing collaboration with Stipple Bio that could be worth up to $5.9 billion, as well as an agreement to acquire Calytrix Bio for $1.5 billion. These deals broaden its oncology pipeline, but development remains uncertain and the stated values are not guaranteed near-term returns. Stipple Bio deal article Calytrix acquisition article
  • Neutral Sentiment: Lilly updated several early-stage studies, including obesity and inflammation programs. The updates indicate ongoing pipeline activity, but the reports provided no clinical results to establish whether the drugs are safe or effective. Obesity study update

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the company. Bank of America reiterated a “buy” rating and issued a $1,497.00 target price on shares of Eli Lilly and Company in a research report on Friday, October 30th. BMO Capital Markets reissued an “outperform” rating and set a $1,650.00 price target on shares of Eli Lilly and Company in a research report on Friday, October 30th. JPMorgan Chase & Co. lifted their price objective on shares of Eli Lilly and Company from $1,500.00 to $1,650.00 and gave the company an “overweight” rating in a research note on Friday, October 30th. Guggenheim lifted their price objective on shares of Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the company a “buy” rating in a research note on Friday, September 18th. Finally, China Merchants Securities downgraded shares of Eli Lilly and Company from a “buy” rating to a “hold” rating in a report on Thursday, November 12th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Eli Lilly and Company has an average rating of “Moderate Buy” and a consensus target price of $1,422.00.

Get Our Latest Analysis on Eli Lilly and Company

Eli Lilly and Company Price Performance

The company has a market capitalization of $1.30 trillion, a price-to-earnings ratio of 44.82, a P/E/G ratio of 1.71 and a beta of 0.40. The stock has a fifty day simple moving average of $1,253.71 and a 200-day simple moving average of $1,114.28. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.39 and a quick ratio of 1.00.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last issued its quarterly earnings data on Thursday, October 29th. The company reported $7.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.71 by $1.77. The firm had revenue of $24.40 billion for the quarter, compared to analyst estimates of $22.58 billion. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 86.76%. Eli Lilly and Company’s revenue was up 38.6% on a year-over-year basis. During the same period in the previous year, the firm earned $7.02 EPS. On average, equities research analysts anticipate that Eli Lilly and Company will post 35.70 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be issued a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 0.5%. The ex-dividend date is Friday, November 13th. Eli Lilly and Company’s dividend payout ratio is currently 22.46%.

Insider Buying and Selling at Eli Lilly and Company

In related news, EVP Anat Hakim sold 5,000 shares of Eli Lilly and Company stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $1,402.52, for a total value of $7,012,600.00. Following the completion of the sale, the executive vice president owned 4,137 shares in the company, valued at approximately $5,802,225.24. This trade represents a 54.72% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.14% of the company’s stock.

Institutional Investors Weigh In On Eli Lilly and Company

Institutional investors and hedge funds have recently modified their holdings of the company. Claris Financial LLC acquired a new stake in Eli Lilly and Company in the third quarter worth $202,000. SK Wealth Management LLC boosted its holdings in shares of Eli Lilly and Company by 12.5% during the third quarter. SK Wealth Management LLC now owns 341 shares of the company’s stock valued at $395,000 after acquiring an additional 38 shares during the period. Brown Financial Advisors grew its position in shares of Eli Lilly and Company by 10.1% during the third quarter. Brown Financial Advisors now owns 1,382 shares of the company’s stock worth $1,600,000 after acquiring an additional 127 shares during the last quarter. Coastal Bridge Advisors LLC grew its position in shares of Eli Lilly and Company by 222.7% during the third quarter. Coastal Bridge Advisors LLC now owns 7,961 shares of the company’s stock worth $9,211,000 after acquiring an additional 5,494 shares during the last quarter. Finally, Harvey Capital Management Inc. increased its holdings in shares of Eli Lilly and Company by 1.5% in the 3rd quarter. Harvey Capital Management Inc. now owns 6,379 shares of the company’s stock worth $7,381,000 after acquiring an additional 92 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Company Profile

(Get Free Report)

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.

Read More

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.